Nothing but negotiation

 
The Gap Partnership

Myriad Genetics completes business negotiations with Melanoma Diagnostics

Myriad Genetics has struck a deal that sees it acquire technology used in the diagnosis of malignant melanoma.

09 December 2010

Myriad Genetics has concluded its business negotiations with Melanoma Diagnostics in a deal that sees the firm acquire propriety technology to assist with the prognosis and diagnosis of malignant melanoma.

As part of the agreement, the company, which states its strategy is to understand the part genes play in human disease, has all rights to commercialise any tests derived from the acquisition.

Commenting on the deal, president of Myriad Genetic Technologies Mark Capone said: "This will expand our presence in the solid tumour market as we develop a dermatology commercialisation team."

Dr Kevin Scanlon, chief executive of Melanoma Diagnostics noted the sale of its technology to Myriad will help towards the future development of novel molecular diagnostic tests.

These latest business negotiations come after Aggreko, the temporary power and control company, acquired Northland Power Services - a supplier of energy solutions - for a maximum consideration of $26 million (£16.6 million). 

Gap News

March 2014

The Negotiation Roadshow 2014

Generating value through creative negotiation

Read more


July 2013

Trading Global: Negotiating in the Far East

The Gap Partnership are hosting a complimentary Lunch & Learn seminar in association with UK Trade & Investment

Read more


April 2013

GroceryAid Negotiation Event Raises £26,550

The Gap Partnership, in conjunction with Asda, SC Johnson and Waitrose, host one-day negotiation workshop

Read more


February 2013

Trading Global - Negotiating in the Far East

What is the impact of cultural differences on your negotiations?

Read more


December 2012

The Gap Partnership Release New Negotiation Video

The Nothing but Negotiation video series continues with collaborative negotiation

Read more